



“An Overview On Biological Behavior Of Benzotriazole: Synthesis And Docking Study On Its Versatile Biological Activities”

Somashekhar Metri^{1*}, Divya Shirke¹, Vishal Babar², Shivanand Kolageri¹

^{1*}Department of Pharmaceutical Chemistry, BLDEA's SSM College of Pharmacy and Research Centre, Vijayapur, Karnataka, India

²Department of Pharmaceutical Chemistry, DKSS Institute of Pharmaceutical Science and Research (For Girls) Swami-Chincholi-413102

***Corresponding Author:** Somashekhar Metri

* Department of pharmaceutical chemistry BLDEA's SSM College of Pharmacy and Research Centre, Vijayapur-586103, E. mail.Id: ssmcop.somashekhar metri@bldea.org, Tel. No: +91-9972087081

Abstract:

The practice of medicinal chemistry is devoted to the discovery and development of new chemical agents for treating diseases. Triazoles are obtained by a slight modification of azole ring and similar or improved activities as well as fewer adverse effects are reported for triazole derivatives several advantages are the notable attraction for using benzotriazole moiety-dependent methodologies, in my research work I synthesized various derivatives of n-(1h-benzotriazol-6-yl)-benzamide from Benzene 1,2,4-triamine and benzoic acid with high yield and the synthesized derivatives characterized by FT-IR spectrum, H¹ NMR spectrum, and mass spectrum data of synthesized derivatives compounds of benzotriazole Scheme analysis proves that resultant compounds n-(1h-benzotriazol-6-yl)-benzamide derivatives. The molecular docking studies validated the outcome results from the anti-inflammatory and antiarthritic agents and signifies the potential of these derivatives as crystal structure of C-terminus of voltage-gated sodium channel in complex (PDB ID:4DCK) and COX 2 Inhibitor (PDB ID:1CX2) inhibitors. So, these compounds can be modified further for the development of new anti-inflammatory and antiarthritic agents. This study strongly suggests that most of molecules synthesized in this study may indeed be promising drug candidates with interesting pharmacological profile and most of these derivatives could be a fruitful for further development of better anti-inflammatory and antiarthritic activity.

CC License
CC-BY-NC-SA 4.0

Keywords: Benzotriazole, Docking study, anti-inflammatory activity, antiarthritic activity.

INTRODUCTION:

The synthesis of novel benzotriazine heterocycles was developed independently around the same time by Bischler, Bamberger and Arndt. Over the years, different groups have reported the synthesis of benzotriazine based compounds. Benzo-condensed azole containing three heteroatoms, such as bezoxadiazole, benzothiazole and benzotriazole [1-5], have been extensively studied for their broad range

of biological activity. However, few reviews were focalized on a single nucleus. Indeed, this paper aims to provide an overview of the benzotriazole based systems and their relevance in medicinal chemistry.

Chemistry: 1H-1, 2, 3-Benzotriazole was synthesized by diazotization of ortho phenylene di amine using glacial acetic acid and sodium nitrate. 2-chloro-N- Alkyl/Aryl acetamide was synthesized by drop wise adding four equivalents of chloroacetyl chloride over one hour to the aqueous amine solution. Finally N-(Alkyl or Aryl)- 2-(1Hbenzotriazol-1-yl)-acetamide derivatives were synthesized by adding 2-chloro-N- Alkyl/Aryl acetamide to 1H-1, 2, 3-Benzotriazole and using anhydrous potassium carbonate as a base.

Rheumatoid arthritis (RA) is an immune-mediated inflammatory disease that is characterized by chronic progressive inflammation and subsequent destruction of peripheral joints, ligaments and tendons [6-8]. The pathogenesis of RA so far has not been fully elucidated. However, inflammatory involvement of the synovium, the lining tissue of diarthrodial joints, tendon sheaths and bursae represent the main process in RA pathology. The inflamed RA synovium is complex and characterized by synovial proliferation, neo angiogenesis and chronic inflammatory cell infiltration. Any of the numerous cell surface receptors, adhesion molecules and growth factors involved in the pathogenesis may serve as potential targets for therapeutic intervention [9-11].

MATERIALS AND METHODS:

All the chemicals used were produced from Sigma Aldrich, Merck and CDH laboratory chemical suppliers and purity of starting materials used for reactions was confirmed by checking their melting point or boiling point and by thin layer chromatography.

The synthetic strategy for target molecules involves following sequence of reaction SCHEME




Figure no:1. Scheme

STEP-I: Synthesis of N-(3,4-diaminophenyl)benzamide

mol of Benzene 1,2,4-triamine treated with 0.01 mol of benzoic acid in presence of 25ml of DMF which is refluxed on water bath for 6hours and the purity of the product was confirmed by a single spot on TLC plate and recrystallized from methanol which gives the N-(3,4-diaminophenyl)benzamide the physicochemical properties of the compound given below table No 7.1.

Table No. 1: Physicochemical properties of N-(3,4-aminophenyl)benzamide

Sl. No	Parameter	N-(3,4-aminophenyl)benzamide
1	Molecular Formula	C ₁₃ H ₁₃ N ₃ O
2	Molecular weight	227.26
3	Theoretical yield	36.71gm
4	Practical yield	34.78gm
5	% yield	94.74%
6	Melting point	99-101 ⁰ C
7	Recrystallization Solvent	Ethanol
8	Solvent for TLC	Cyclohexane: Chloroform 1:1
9	R _f Value	0.90

Step-II Synthesis of n-(1h-benzotriazol-6-yl)-benzamide

0.05mol of n-(3,4-diaminophenyl) benzamide refluxed with 15ml of acetic acid in 5gm of sodium nitrate stirred continuously with maintain constant temperature 15°C then the reaction mixture gives the brown color precipitate after cooling the purity of the product was confirmed by a single spot on TLC plate and recrystallized from methanol which gives the N-(3,4-diaminophenyl)benzamide the physicochemical properties of the compound given below table No 2.

Table No. 2: Physicochemical properties of n-(1h-benzotriazol-6-yl)-benzamide

Sl. No	Parameter	n-(1h-benzotriazol-6-yl)-benzamide
1	Molecular Formula	C ₁₃ H ₁₀ N ₄ O
2	Molecular weight	238.24
3	Theoretical yield	34.78gm
4	Practical yield	31.66gm
5	% yield	91.02%
6	Melting point	110-112 ⁰ C
7	Recrystallization Solvent	Ethanol
8	Solvent for TLC	Cyclohexane: Chloroform 1:1
9	R _f Value	0.96

Step-III Synthesis of derivatives of n-(1h-benzotriazol-6-yl)-benzamide

A mixture of n-(1h-benzotriazol-6-yl)-benzamide (6gm, 1 mol) in DMF (25ml) and various substituted aromatic halides (RCH₂X) (3.3ml, 0.5 mol) was refluxed on a water bath for 6-8 hrs. Excess of halides was removed by distillation under reduced pressure Collected product was recrystallized from ethanol. The purity of the product was confirmed by a single spot-on TLC plate and physicochemical properties of Derivatives n-(1h-benzotriazol-6-yl)-benzamide given below table No 3 to 4

IR N-H Stretch of 3⁰ amine -3323.81 cm⁻¹, N-H Stretch Of 2⁰ amine 2956.69 cm⁻¹, Aromatic C-H Stretch 2923.27 cm⁻¹, Aliphatic C-H Stretch 2810.52 cm⁻¹, C = O Stretch 1633.10 cm⁻¹, -NO₂ Stretch 1269.64 cm⁻¹, -CH₃ stretch 959.14 cm⁻¹.




Table No 3: physicochemical properties of Derivatives of n-(1h-benzotriazol-6-yl)-benzamide (D13, D16, and D21)

Sl. No	Parameter	D13	D16	D21
1	Molecular Formula	C ₂₀ H ₁₅ N ₅ O ₃	C ₂₂ H ₁₈ N ₄ O ₂	C ₂₁ H ₁₆ N ₄ O ₃
2	Molecular weight	373.36	370.40	372.37
3	Theoretical yield	5.00gm	5.00gm	5.00gm
4	Practical yield	3.68gm	3.87gm	3.94gm
5	% yield	73.60%	77.40%	78.80%
6	Melting point	112-114 ⁰ C	116-118 ⁰ C	108-110 ⁰ C
7	Recrystallization Solvent	Ethanol	Ethanol	Ethanol
8	TLC	Benzene: n-butanol 1:5	Benzene: n-butanol 1:5	Benzene: n-butanol 1:5
9	R _f Value	0.90	1.02	0.88

Table No 4: physicochemical properties of Derivatives of n-(1h-benzotriazol-6-yl)-benzamide (D13, D16, and D21)

Sl. No	Parameter	D27	D38	D43
1	Molecular Formula	C ₂₁ H ₁₇ N ₅ O ₃	C ₂₀ H ₁₅ N ₄ O ₂ F	C ₂₃ H ₂₀ N ₄ O ₃
2	Molecular weight	387.39	362.35	400.42
3	Theoretical yield	5.00gm	5.00gm	5.00gm
4	Practical yield	3.98gm	3.87gm	3.74gm
5	% yield	79.60%	77.40%	74.80%
6	Melting point	102-104 ⁰ C	106-108 ⁰ C	100-102 ⁰ C
7	Recrystallization Solvent	Ethanol	Ethanol	Ethanol
8	TLC	Benzene:Methanol 1:5	Benzene:Methanol 1:5	Benzene:Methanol 1:5
9	R _f Value	0.89	0.88	0.90

SYNTHESIZED DERIVATIVES**Table No:5. Synthesized *Derivatives of n-(1h-benzotriazol-6-yl)-benzamide***

D13	 <i>N</i>-[1-(3-nitrobenzyl)-1<i>H</i>-benzotriazol-4-yl]benzamide
D16	 <i>N</i>-{1-[(4-acetylphenyl)methyl]-1<i>H</i>-benzotriazol-4-yl}benzamide
D21	 2-[(4-benzamido-1<i>H</i>-benzotriazol-1-yl)methyl]benzoic acid




D27	 <i>N</i>-{1-[(4-methyl-3-nitrophenyl)methyl]-1<i>H</i>-benzotriazol-4-yl}benzamide
D38	 <i>N</i>-{1-[(4-fluoro-3-hydroxyphenyl)methyl]-1<i>H</i>-benzotriazol-4-yl}benzamide
D43	 <i>N</i>-(1-{[3-acetyl-5-(hydroxymethyl)phenyl]methyl}-1<i>H</i>-benzotriazol-4-yl)benzamide

Table no: 6. Molecular Docking scores of selected compounds with COX 2 Inhibitor (PDB ID:1CX2)

Ligand	Binding Affinity
D1	-9.8
D2	-10.3
D3	-9.4
D4	-9.6
D5	-10.5
D6	-10.6
D7	-8.9
D8	-9.9
D9	-9.7
D10	-10.9
D11	-10.5

D12	-10.5
D13	-9.4
D14	-9.1
D15	-10.8
D16	-10
D17	-10.4
D18	-11.1
D19	-11.1
D20	-10.5
D21	-10.3
D22	-9.5
D23	-10
D24	-11.3
D25	-9.9
D26	-9.8
D27	-11.1
D28	-9.7
D29	-10.1
D30	-10.8
D31	-9.5
D32	-9.7
D33	-9.8
D34	-11.2
D35	-9.6
D36	-9.7
D37	-9.9
D38	-10.8
D39	-9.5
D40	-10.3
D41	-10
D42	-10.4
D43	-9.6
D44	-9.7
D45	-10.2
D46	-9.7
D47	-8.4
D48	-10.9
D49	-9.5
D50	-10.4
Indomethacin	-9.8




Figure No 2. 3D and 2D Interactions of D32 with COX 2 Inhibitor (PDB ID:1CX2)




Figure No 3. 3D and 2D Interactions of D33 with COX 2 Inhibitor (PDB ID:1CX2)




Figure No 4. 3D and 2D Interactions of D34 with COX 2 Inhibitor (PDB ID:1CX2)

However, the study showed that all the compounds synthesised are potential for the anticancer activity and can be selected based on further *in-vitro* and *in-vivo* activity studies.

In vitro antiarthritic activity

Protein Denaturation Method


- Test solution (0.5ml): It consist of 0.05ml of test solution of various concentrations (500µg/ml) and 0.45 ml of Bovine serum albumin (5% aqueous solution)
- Test controlsolution (0.5ml): It consist of 0.05ml of distilled water and 0.45ml of Bovine serum albumin (5% aqueous solution).
- Product control (0.5ml): It consist of 0.05ml test solution of concentration (500µg/ml) and 0.45ml of distilled water.
- Standard solution (0.5ml): It consist of 0.05ml of Diclofenac sodium (500µg/ml) and 0.45ml of Bovine serum albumin (5%aqueous solution). PH was adjusted to 6.3 to all above solution by using 1N HCl.
- All the sample solution was incubated at 37°C for 20 minutes and the temperature was increased to 57°C for 3 minutes. Allow the solution to cool for some time then add 2.5ml of Phosphate buffer to all above solution.
- Absorbance of the resulting solution is measured at 660 nm using UV visible spectrophotometer. The Percentage inhibition of protein denaturation was calculated as per the given formula

$$\% \text{ inhibition} = 100 - \frac{(\text{OD of test solution} - \text{OD of product control})}{\text{OD of test control}} \times 100$$

In-vitro anti-inflammatory Activity of derivatives of n-(1h-benzotriazol-6-yl)-benzamide

Table No. 7: *In-vitro* anti-inflammatory Activity of derivatives of n-(1h-benzotriazol-6-yl)-benzamide

Comp code	% Inhibition		
	250µgm	500 µgm	Average
D13	42.15	57.39	56.29
D16	48.13	62.66	58.66
D21	44.21	60.45	58.70
D27	60.16	72.63	66.54
D38	56.60	65.33	63.78
D43	42.10	56.38	55.60
IBUPROFEN	78.18	86.36	85.22

**Figure No. 5: *In-vitro* anti-inflammatory Activity of derivatives of n-(1h-benzotriazol-6-yl)-benzamide**

In-vitro Anti-inflammatory activity was carried out using Bovine Serum albumin denaturation method. All the title compounds (D13, D16, D21, D27, D38 and D43) were screened for anti-inflammatory activity. The results of the anti-inflammatory activity of the compounds are shown in the table No. 9.1 and Figure No. 9.1. D27 showed good activity, whereas other compounds showed mild to poor anti-inflammatory activity.

***In-vitro* antiarthritic Activity of derivatives of n-(1h-benzotriazol-6-yl)-benzamide**

Table No. 8: *In-vitro* anti-arthritis Activity of derivatives of n-(1h-benzotriazol-6-yl)-benzamide

Comp code	% Inhibition		
	250µgm	500 µgm	Average
D13	24.12	46.79	36.41
D16	29.41	55.28	42.02
D21	31.45	59.74	45.16
D27	55.67	76.92	66.13
D38	30.64	58.73	44.59
D43	42.94	66.74	54.67
DICLOFENAC SODIUM	78.67	90.46	84.63




Figure No. 6: *In-vitro* anti-arthritis Activity of derivatives of *n*-(1*h*-benzotriazol-6-yl)-benzamide

In vitro antiarthritic activity Protein Denaturation method the production of auto antigen in certain arthritic disease may be due to denaturation of protein. Percentage inhibition was found to be 66.13% and the effect was compared with standard drug (Diclofenac sodium). *In-vitro* studies which were carried out by the above-mentioned methods proved that the D27 compound possess anti-inflammatory and antiarthritic activity which was similar to that of standards.

RESULTS AND DISCUSSION:

The intermediates converted into corresponding derivatives and they were obtained in high purity with good yield. The FT-IR studies show peaks at $1600-1790\text{ cm}^{-1}$ C=O stretch proves formation of derivatives of corresponding structure *n*-(1*h*-benzotriazol-6-yl)-benzamide derivatives and these derivatives will be tested for their biological activities.

Docking studies were carried out to analyse the different types of biomolecular interactions and ligand receptor binding affinities. The docking studies were carried out by means of Autodock vina, Biovia Discovery Studio 2020, PyRX, and PyMOL. The docking study was performed on proteins namely crystal structure of C-terminus of voltage-gated sodium channel in complex (PDB ID:4DCK) and COX 2 Inhibitor (PDB ID:1CX2) proteins. The computational work was performed on a HP 15s-eq0132au Laptop running on AMD Ryzen 7 3700U processor.

Compounds D13, D16, D21, D27, D38 and D43 reported the excellent docking score with crystal structure of C-terminus of voltage-gated sodium channel in complex (PDB ID:4DCK) and COX 2 Inhibitor (PDB ID:1CX2) proteins as anti-inflammatory and antiarthritic agents

In-vitro Anti-inflammatory activity was carried out using Bovine Serum albumin denaturation method. All the title compounds (D13, D16, D21, D27, D38 and D43) were screened for anti-inflammatory activity. The results of the anti-inflammatory activity of the compounds are shown in the table No. 9.1 and Figure No. 9.1. D27 showed good activity, whereas other compounds showed mild to poor anti-inflammatory activity.

CONCLUSION:

In vitro antiarthritic activity Protein Denaturation method the production of auto antigen in certain arthritic disease may be due to denaturation of protein. Percentage inhibition was found to be 66.13% and the effect was compared with standard drug (Diclofenac sodium). *In-vitro* studies which were carried out by the above-mentioned methods proved that the D27 compound possess anti-inflammatory and antiarthritic activity which was similar to that of standards.

Acknowledgment: The author acknowledges the BLDEA's SSM College of Pharmacy and Research Centre, Vijayapura, BLDE Deemed University, Karnataka for providing the opportunity and resources necessary for me to complete my research work and for encouraging us throughout the research project.

Conflict of interests:

None

REFERENCE:

1. H Zhou C, Wang Y. Recent researches in triazole compounds as medicinal drugs. *Current medicinal chemistry*. 2012; 19(2):239-80.
2. Szilagyi G, Somorai T, Bozó É, Langó J, Nagy G, Reiter J, Janáky J, András F. Preparation and antiarthritic activity of new 1, 5-diaryl-3-alkylthio-1H-1, 2, 4-triazoles and corresponding sulfoxides and sulfones. *European journal of medicinal chemistry*. 1990; 25(2):95-101.
3. Maertens JA. History of the development of azole derivatives. *Clinical Microbiology and Infection*. 2004 Mar;10:1-0.
4. K.P. Barot, S. Nikolova, I. Ivanov, M.D. Ghate, Novel research strategies of benzimidazole derivatives: a review, *Mini Rev. Med. Chem*. 13 (2013) 1421e1447.
5. Q.A. McKellar, E.W. Scott, The benzimidazole anthelmintic agents e a review, *J. Vet. Pharmacol. Ther*. 13 (1990) 223e247.
6. A.P. Piccionello, A. Guarcello, Bioactive compounds containing benzoxadiazole, benzothiadiazole, benzotriazole, *Curr. Bioact. Compd*. 6 (2010) 266e283.
7. B.V. Suma, N.N. Natesh, V. Madhavan, Benzotriazole in medicinal chemistry: an overview, *J. Chem. Pharm. Res*. 3 (2011) 375e381.
8. Furmiss BS, Hannaford AJ, Smith PWG, Tatchell AR. *Vogel's textbook of practical organic chemistry*. Pearson . 2008, (5), 1163.
9. L.N. Davis, J. Santodonato, P. Howard, J. Saxena, Investigation of Selected Potential Environmental Contaminants: Benzotriazoles. Final Report Prepared for Office of Toxic Substances, US Environmental Protection Agency, Washington, DC, 1977.
10. C. Sease, *Stud. Conserv* 23 (2) (1978) 76–85.
11. Katritzky AR, Rachwal S, Hitchings GJ. Benzotriazole: a novel synthetic auxiliary. *Tetrahedron*. 1991 Jan 1;47(16-17):2683-732.
12. Katritzky AR, Shobana N, Pernak J, Afridi AS, Fan WQ. Sulfonyl derivatives of benzotriazole: Part 1. A novel approach to the activation of carboxylic acids. *Tetrahedron*. 1992 Jan 1;48(37):7817-22.
13. Katritzky AR, Manju K, Singh SK, Meher NK. Benzotriazole mediated amino-, amido-, alkoxy- and alkylthio-alkylation. *Tetrahedron*. 2005 Mar 7;61(10):2555-81.
14. Katritzky AR, Qiu G, Yang B, He HY. Novel syntheses of indolizines and pyrrolo [2, 1-a] isoquinolines via benzotriazole methodology. *The Journal of Organic Chemistry*. 1999 Oct 1;64(20):7618-21.
15. Katritzky AR, Rachwal S. Synthesis of heterocycles mediated by benzotriazole. 1. Monocyclic systems. *Chemical reviews*. 2010 Mar 10;110(3):1564-610.
16. Kale RR, Prasad V, Mohapatra PP, Tiwari VK. Recent developments in benzotriazole methodology for construction of pharmacologically important heterocyclic skeletons. *Monatshefte für Chemie-Chemical Monthly*. 2010 Nov;141:1159-82.
17. Verma AK, Singh J, Sankar VK, Chaudhary R, Chandra R. Benzotriazole: an excellent ligand for Cu-catalyzed N-arylation of imidazoles with aryl and heteroaryl halides. *Tetrahedron letters*. 2007 Jun 11;48(24):4207-10.
18. Katritzky AR, Jiang R, Suzuki K. N-Tfa- and N-Fmoc-(α -aminoacyl) benzotriazoles as Chiral C-Acylating Reagents under Friedel– Crafts Reaction Conditions. *The Journal of Organic Chemistry*. 2005 Jun 24;70(13):4993-5000.
19. Tani S, Arisawa M, Tougo T, Yamaguchi M. Catalytic Method for the Synthesis of C–N-Linked Bi (heteroaryl) s Using Heteroaryl Ethers and N-Benzoyl Heteroarenes. *Organic letters*. 2018 Mar 12;20(7):1756-9.
20. Katritzky AR, Drewniak M. The chemistry of benzotriazole. Part 8. A novel two-step procedure for the N-alkylation of amides. *Journal of the Chemical Society, Perkin Transactions 1*. 1988(8):2339-44.
21. Katritzky AR, Qi M. Michael Additions of Benzotriazole-Stabilized Carbanions. A Review. *Collection of Czechoslovak chemical communications*. 1998;63(5):599-613.
22. Katritzky AR, Ignatchenko AV, Lang H. Generalization of the Benzotriazole-Mediated Introduction of N-Substituents into Amides. *The Journal of Organic Chemistry*. 1995 Jun;60(13):4002-5.
23. Panda SS, Hall CD, Scriven E, Katritzky AR. Aminoacyl benzotriazolides: versatile reagents for the preparation of peptides and their mimetics and conjugates. *Aldrichimica Acta*. 2013 Jan 1;46(2):43-58.
24. Albers T, Watkins DL, Gameiro AF, Povstyanoy VY, Povstyanoy MV, Lebedyeva IO. Benzotriazole-based

- strategies toward peptidomimetics, conjugates, and other peptide derivatives. *The Chemistry of Benzotriazole Derivatives: A Tribute to Alan Roy Katritzky*. 2016:95-141.
25. Ibrahim MA, Panda SS, Oliferenko AA, Oliferenko PV, Girgis AS, Elagawany M, Küçükbay FZ, Panda CS, Pillai GG, Samir A, Tamm K. Macrocyclic peptidomimetics with antimicrobial activity: synthesis, bioassay, and molecular modeling studies. *Organic & Biomolecular Chemistry*. 2015;13(36):9492-503.
 26. Panda SS, Jones RA, Dennis Hall C, Katritzky AR. Applications of chemical ligation in peptide synthesis via acyl transfer. *Protein Ligation and Total Synthesis I*. 2015:229-65.
 27. Avan I, Hall CD, Katritzky AR. Peptidomimetics via modifications of amino acids and peptide bonds. *Chemical Society Reviews*. 2014;43(10):3575-94.
 28. Briguglio I, Piras S, Corona P, Gavini E, Nieddu M, Boatto G, Carta A. Benzotriazole: An overview on its versatile biological behavior. *European Journal of Medicinal Chemistry*. 2015 Jun 5;97:612-48.
 29. Liu X, Cheng Y, Wang W, Liu F, Hou B. Application of 1D attapulgit as reservoir with benzotriazole for corrosion protection of carbon steel. *Materials Chemistry and Physics*. 2018 Feb 1;205:292-302.
 30. Farkas R, Törincsi M, Kolonits P, Fekete J, Alonso O, Novak L. Simultaneous displacement of a nitro group during coupling of diazotized o-nitroaniline with phenols. *Open Chemistry*. 2010 Apr 1;8(2):300-7.
 31. Peng B, Najari A, Liu B, Berrouard P, Gendron D, He Y, Zhou K, Zou Y, Leclerc M. A new dithienylbenzotriazole-based poly (2, 7-carbazole) for efficient photovoltaics. *Macromolecular Chemistry and Physics*. 2010 Sep 15;211(18):2026-33.
 32. Bajaj K, Sakhuja R. Benzotriazole: Much more than just synthetic heterocyclic chemistry. *The Chemistry of Benzotriazole Derivatives: A Tribute to Alan Roy Katritzky*. 2016:235-83.
 33. Srinivas D, Ghule VD, Tewari SP, Muralidharan K. Synthesis of Amino, Azido, Nitro, and Nitrogen-Rich Azole-Substituted Derivatives of 1H-Benzotriazole for High-Energy Materials Applications. *Chemistry—A European Journal*. 2012 Nov 19;18(47):15031-7.
 34. Al-Jibori SA, Al-Doori LA, Al-Janabi AS, Alheety MA, Akbaş H, Karadag A. Novel Hg (II) and Pd (II) benzotriazole (Hbta) complexes: Synthesis, characterization, X-ray crystal structure of [Pd (PPh₃)(μ-bta) Cl] 2. DMSO and thermodynamic study of their H₂ storage. *Journal of Molecular Structure*. 2020; 5(1207):127832.
 35. Sert-Ozgur S, Tel BC, Somuncuoglu EI, Kazkayasi I, Ertan M, Tozkoparan B. Design and Synthesis of 1, 2, 4-Triazolo [3, 2-b]-1, 3, 5-thiadiazine Derivatives as a Novel Template for Analgesic/Anti-Inflammatory Activity. *Archiv der Pharmazie*. 2017; 350(7):e1700052.
 36. Azim T, Wasim M, Akhtar MS, Akram I. An in vivo evaluation of anti-inflammatory, analgesic and anti-pyretic activities of newly synthesized 1, 2, 4 Triazole derivatives. *BMC Complementary Medicine and Therapies*. 2021; 21(1):1-5.
 37. H Zhou C, Wang Y. Recent researches in triazole compounds as medicinal drugs. *Current medicinal chemistry*. 2012; 19(2):239-80.
 38. Szilagyí G, Somorai T, Bozó É, Langó J, Nagy G, Reiter J, Janáky J, András F. Preparation and antiarthritic activity of new 1, 5-diaryl-3-alkylthio-1H-1, 2, 4-triazoles and corresponding sulfoxides and sulfones. *European journal of medicinal chemistry*. 1990; 25(2):95-101.
 39. Dawood KM, Abdel-Gawad H, Rageb EA, Ellithy M, Mohamed HA. Synthesis, anticonvulsant, and anti-inflammatory evaluation of some new benzotriazole and benzofuran-based heterocycles. *Bioorganic & medicinal chemistry*. 2006; 14(11):3672-80.
 40. Briguglio I, Piras S, Corona P, Gavini E, Nieddu M, Boatto G, Carta A. Benzotriazole: An overview on its versatile biological behavior. *European journal of medicinal chemistry*. 2015; 5(97):612-48.
 41. Anukanon S, Pongpamorn P, Tiabhorn W, Chatwichien J, Niwetmarin W, Sessions RB, Ruchirawat S, Thasana N. In Silico-Guided Rational Drug Design and Semi-synthesis of C (2)-Functionalized Huperzine A Derivatives as Acetylcholinesterase Inhibitors. *ACS omega*. 2021; 6(30):19924-39.
 42. Jones Lipinski RA, Thillier Y, Morisseau C, Sebastiano Jr CS, Smith BC, Hall CD, Katritzky AR. Molecular docking-guided synthesis of NSAID–glucosamine bioconjugates and their evaluation as COX-1/COX-2 inhibitors with potentially reduced gastric toxicity. *Chemical biology & drug design*. 2021; 98(1):102-13.
 43. Nasri S, Bayat M, Kochia K. Strategies for synthesis of 1, 2, 4-triazole-containing scaffolds using 3-amino-1, 2, 4-triazole. *Molecular Diversity*. 2021; 19:1-23.
 44. Szczukowski Ł, Krzyżak E, Wiatrak B, Jawień P, Marciniak A, Kotynia A, Świątek P. New N-Substituted-1, 2, 4-Triazo
 45. le Derivatives of Pyrrolo [3, 4-d] Pyridazinone with Significant Anti-Inflammatory Activity—Design, Synthesis and Complementary In Vitro, Computational and Spectroscopic Studies. *International journal of molecular sciences*. 2021; 22(20):11235.
 46. Li J, Han D, Zhang Q, He Z, Lu Y. Synthesis and properties of fluorinated benzotriazole-based donor-

- acceptor-type conjugated polymers via Pd-catalyzed direct C–H/C–H coupling polymerization. *Journal of Polymer Science*. 2021; 59(3):240-50.
47. Yu J, Singh AS, Yan G, Yu J, Tiwari VK. Recent Developments on Denitrogenative Functionalization of Benzotriazoles. *Synthesis*. 2020; 52(24):3781-800.
 48. Ling N, Wang X, Zeng D, Zhang YW, Fang X, Yang HX. Synthesis, characterization and biological assay of three new benzotriazole-based Zn (II) complexes. *Journal of Molecular Structure*. 2020; 1206:127641
 49. Anjana VS, Kumar PM. An Overview on Medicinal Perspective and Biological Behavior of Benzotriazole; Synthetic Study on Its Multifaceted Biological Activities.
 50. Datta A, Alpana A, Shrikant M, Pratyush K, Abhibnav B, Ruchita T. Review on synthetic study of benzotriazole. *GSC Biological and Pharmaceutical Sciences*. 2020;11(2):215-25.
 51. Bokhtia RM, Panda SS, Girgis AS, Pillai GG, Ibrahim TS, Shalaby EM, Gigli L, Abdel-Aal EH, Al-Mahmoudy AM. Efficient Synthesis and Computational Studies of Useful Guanylated Agents: 1H-Benzotriazole-1-carboximidamides. *Chemistry Select*. 2020; 5(44):13963-8